Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference

Rhea-AI Summary

Esperion (NASDAQ: ESPR) has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference scheduled for May 20, 2025, at 10 a.m. ET. The event will be webcasted and accessible through Esperion's website, with replay available for approximately 90 days after the presentation.

Esperion is a commercial-stage biopharmaceutical company that develops FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi) development.

News Market Reaction

-10.60%

1 alert

-10.60% News Effect

On the day this news was published, ESPR declined 10.60%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3^rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET.

The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.

Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.

Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Esperion Contact Information: 
Investors:  
Alina Venezia 
investorrelations@esperion.com
(734) 887-3903 

Media:  
Tiffany Aldrich  
corporateteam@esperion.com
(616) 443-8438 

FAQ

When is Esperion (ESPR) presenting at the H.C. Wainwright BioConnect Conference 2025?

Esperion (ESPR) is presenting at the H.C. Wainwright BioConnect Conference on May 20, 2025, at 10 a.m. ET.

What are Esperion's (ESPR) main products and focus?

Esperion develops FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C, supported by the CLEAR Cardiovascular Outcomes Trial with nearly 14,000 patients.

What is Esperion's (ESPR) next-generation research program?

Esperion's next-generation program focuses on developing ATP citrate lyase inhibitors (ACLYi) with highly potent and specific inhibitors using allosteric mechanisms.

How long will the webcast replay be available on Esperion's website?

The webcast replay will be available approximately two hours after the presentation and will be archived on Esperion's website for approximately 90 days.